Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Explore telltale signs your budget isn’t working and why those signals appear, plus simple fixes to regain financial control.
18,418 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Biotech headlines move markets. ImmunityBio, boosted by Anktiva's 700% revenue surge, sparked a rally that may signal...
Cava's yearly revenue just crossed the $1 billion mark, signaling a major milestone for the fast-casual chain. This a...
As AI builds demand for data centers, most giants plow assets into expansion. One tech leader bucking the trend could...
A volatile March sell-off reshaped sentiment around Western Digital and Seagate. Western Digital’s move to fortify it...
A coalition pairing HBCUs with fintech and civil rights groups frames AI as the most important civil human issue of o...
Is $900,000 enough outlast rmds? A closer look at 2026 retirement math shows a first-year withdrawal around $34,000 o...
A wave of enthusiasm for AI infrastructure helped Tower Semiconductor leap higher this week. Investors spotlighted si...
In a year marked by rapid AI expansion, memory plays have emerged as a quiet engine behind stock gains. This hidden s...
A 62-year-old retiree weighs a $500,000 Roth conversion over five years to reduce future RMDs, with an upfront tax bi...
Canada's online brokerage scene is evolving as fee cuts and wider cross-border access reshape investor options. Here ...
Self-employed workers who filed paper returns in the 1990s may have missing earnings data, risking tens of thousands ...